These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 21471424)

  • 21. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.
    Cohen V; Panet-Raymond V; Sabbaghian N; Morin I; Batist G; Rozen R
    Clin Cancer Res; 2003 May; 9(5):1611-5. PubMed ID: 12738713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Yamada H; Iinuma H; Watanabe T
    Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.
    Kristensen MH; Pedersen PL; Melsen GV; Ellehauge J; Mejer J
    J Int Med Res; 2010; 38(3):870-83. PubMed ID: 20819423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
    Dotor E; Cuatrecases M; Martínez-Iniesta M; Navarro M; Vilardell F; Guinó E; Pareja L; Figueras A; Molleví DG; Serrano T; de Oca J; Peinado MA; Moreno V; Germà JR; Capellá G; Villanueva A
    J Clin Oncol; 2006 Apr; 24(10):1603-11. PubMed ID: 16575011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.
    Etienne-Grimaldi MC; Milano G; Maindrault-Goebel F; Chibaudel B; Formento JL; Francoual M; Lledo G; André T; Mabro M; Mineur L; Flesch M; Carola E; de Gramont A
    Br J Clin Pharmacol; 2010 Jan; 69(1):58-66. PubMed ID: 20078613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
    van Kuilenburg AB
    Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy.
    Paré L; Altés A; Ramón y Cajal T; Del Rio E; Alonso C; Sedano L; Barnadas A; Baiget M
    Anticancer Drugs; 2007 Aug; 18(7):821-5. PubMed ID: 17581305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity.
    Jakobsen A; Nielsen JN; Gyldenkerne N; Lindeberg J
    J Clin Oncol; 2005 Mar; 23(7):1365-9. PubMed ID: 15735113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.
    Lamas MJ; Duran G; Gomez A; Balboa E; Anido U; Bernardez B; Rana-Diez P; Lopez R; Carracedo A; Barros F
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):138-44. PubMed ID: 21167658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. One-carbon metabolism related gene polymorphisms interact with alcohol drinking to influence the risk of colorectal cancer in Japan.
    Matsuo K; Ito H; Wakai K; Hirose K; Saito T; Suzuki T; Kato T; Hirai T; Kanemitsu Y; Hamajima H; Tajima K
    Carcinogenesis; 2005 Dec; 26(12):2164-71. PubMed ID: 16051637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A case-control study on the polymorphisms of methylenetetrahydrofolate reductases, drinking interaction and susceptibility in colorectal cancer].
    Jiang QT; Chen K; Ma XY; Miao XP; Yao KY; Yu WP; Li LY; Zhu YM; Zhou HG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jul; 25(7):612-6. PubMed ID: 15308044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer.
    Zhang W; Press OA; Haiman CA; Yang DY; Gordon MA; Fazzone W; El-Khoueiry A; Iqbal S; Sherrod AE; Lurje G; Lenz HJ
    J Clin Oncol; 2007 Aug; 25(24):3726-31. PubMed ID: 17704422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
    Ruzzo A; Graziano F; Loupakis F; Rulli E; Canestrari E; Santini D; Catalano V; Ficarelli R; Maltese P; Bisonni R; Masi G; Schiavon G; Giordani P; Giustini L; Falcone A; Tonini G; Silva R; Mattioli R; Floriani I; Magnani M
    J Clin Oncol; 2007 Apr; 25(10):1247-54. PubMed ID: 17401013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil.
    Iacopetta B; Grieu F; Joseph D; Elsaleh H
    Br J Cancer; 2001 Sep; 85(6):827-30. PubMed ID: 11556832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
    Roberto M; Romiti A; Botticelli A; Mazzuca F; Lionetto L; Gentile G; Paris I; Falcone R; Bassanelli M; Di Pietro FR; Onesti CE; Anselmi E; Macrini S; Simmaco M; Marchetti P
    Eur J Clin Pharmacol; 2017 Feb; 73(2):157-164. PubMed ID: 27864592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case-control study.
    Lin J; Spitz MR; Wang Y; Schabath MB; Gorlov IP; Hernandez LM; Pillow PC; Grossman HB; Wu X
    Carcinogenesis; 2004 Sep; 25(9):1639-47. PubMed ID: 15117811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Data-driven assessment of the association of polymorphisms in 5-Fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer.
    Sarac SB; Rasmussen CH; Afzal S; Thirstrup S; Jensen SA; Colding-Jørgensen M; Poulsen HE; Mosekilde E
    Basic Clin Pharmacol Toxicol; 2012 Sep; 111(3):189-97. PubMed ID: 22448752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MTHFR and MTRR genotype and haplotype analysis and colorectal cancer susceptibility in a case-control study from the Czech Republic.
    Pardini B; Kumar R; Naccarati A; Prasad RB; Forsti A; Polakova V; Vodickova L; Novotny J; Hemminki K; Vodicka P
    Mutat Res; 2011 Mar; 721(1):74-80. PubMed ID: 21211571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis.
    Kumagai K; Hiyama K; Oyama T; Maeda H; Kohno N
    Int J Mol Med; 2003 May; 11(5):593-600. PubMed ID: 12684695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.
    Nahid NA; Apu MNH; Islam MR; Shabnaz S; Chowdhury SM; Ahmed MU; Nahar Z; Islam MS; Islam MS; Hasnat A
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):119-129. PubMed ID: 29134491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.